# Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

> **NCT03669445** · PHASE2 · UNKNOWN · sponsor: **University Hospital, Toulouse** · enrollment: 45 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03669445
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-31
- **Primary completion:** 2024-03
- **Final completion:** 2024-12
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03669445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03669445, "Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03669445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*